In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death

Athanasios Vassilopoulos; Eleftherios Mylonakis

doi:10.7326/J22-0038

In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death

Ann Intern Med. 2022 Jun;175(6):JC63. doi: 10.7326/J22-0038. Epub 2022 Jun 7.

Authors

Athanasios Vassilopoulos¹, Eleftherios Mylonakis¹

Affiliation

¹ Rhode Island Hospital and The Miriam Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA (A.V., E.M.).

PMID: 35667068
DOI: 10.7326/J22-0038

Abstract

Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397-408. 35172054.

Publication types

Comment

MeSH terms

Adult
COVID-19 Drug Treatment*
Hospitalization
Humans
Ritonavir / therapeutic use

Substances

Ritonavir